Hao Li

Dr. Hao Li


Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 July 2022 in Journal of Autoimmunity
Verified
Journal Article
Closed access
HLHao Li
Hao Li
ABAfroditi Boulougoura
Afroditi Boulougoura
YEYushiro Endo
Yushiro Endo
GTGeorge Tsokos
George Tsokos

1 March 2021 in Current Opinion in Rheumatology
Verified
Journal Article
Closed access
HLHao Li
Hao Li
GTGeorge Tsokos
George Tsokos
Purpose of review: TCRαβ+CD4-CD8- double-negative T (DNT) cells, a principal subset of mature T lymphocytes, have been closely linked with autoimmune/inflammatory conditions. However, controversy persists regarding their ontogeny and function. Here, we present an overview on DNT cells in different autoimmune diseases to advance a deeper understanding of the contribution of this population to disease pathogenesis. Recent findings: DNT cells have been characterized in various chronic inflammatory diseases and they have been proposed to display pathogenic or regulatory function. The tissue location of DNT cells and the effector cytokines they produce bespeak to their active involvement in chronic inflammatory diseases. Summary: By producing various cytokines, expanded DNT cells in inflamed tissues contribute to the pathogenesis of a variety of autoimmune inflammatory diseases. However, it is unclear whether this population represents a stable lineage consisting of different subsets similar to CD4+ T helper cell subset. Better understanding of the possible heterogeneity and plasticity of DNT cells is needed to reveal interventional therapeutic opportunities.

15 March 2016 in The Journal of Immunology
Verified
Journal Article
Closed access
PDF file
MZMingce Zhang
Mingce Zhang
CBClaudia Bracaglia
Claudia Bracaglia
GPGiusi Prencipe
Giusi Prencipe
CBChristina J. Bemrich-Stolz
Christina J. Bemrich-Stolz
TBTimothy Beukelman
Timothy Beukelman
RCRandy Q. Cron
Randy Q. Cron
Frequently fatal, primary hemophagocytic lymphohistiocytosis (HLH) occurs in infancy resulting from homozygous mutations in NK and CD8 T cell cytolytic pathway genes. Secondary HLH presents after infancy and may be associated with heterozygous mutations in HLH genes. We report two unrelated teenagers with HLH and an identical heterozygous RAB27A mutation (c.259G→C). We explore the contribution of this Rab27A missense (p.A87P) mutation on NK cell cytolytic function by cloning it into a lentiviral expression vector prior to introduction into the human NK-92 cell line. NK cell degranulation (CD107a expression), target cell conjugation, and K562 target cell lysis was compared between mutant– and wild-type–transduced NK-92 cells. Polarization of granzyme B to the immunologic synapse and interaction of mutant Rab27A (p.A87P) with Munc13-4 were explored by confocal microscopy and proximity ligation assay, respectively. Overexpression of the RAB27A mutation had no effect on cell conjugate formation between the NK and target cells but decreased NK cell cytolytic activity and degranulation. Moreover, the mutant Rab27A protein decreased binding to Munc13-4 and delayed granzyme B polarization toward the immunologic synapse. This heterozygous RAB27A mutation blurs the genetic distinction between primary and secondary HLH by contributing to HLH via a partial dominant-negative effect.

16 May 2014 in Arthritis & Rheumatology
Verified
Journal Article
Open access
PDF file
JLJun Li
Jun Li
HHHui‐Chen Hsu
Hui‐Chen Hsu
YDYana Ding
Yana Ding
HLHao Li
Hao Li
QWQi Wu
Qi Wu
John D. MountzJohn D. Mountz
John D. Mountz
Objective: Fucosylation catalyzed by fucosyltransferases (FUTs) is an important posttranslational modification involved in a variety of biologic processes. This study was undertaken to determine the roles of fucosylation in rheumatoid arthritis (RA) and to assess the efficacy of reestablishing immune homeostasis with the use of 2‐deoxy‐d‐galactose (2‐d‐gal), a fucosylation inhibitor.Methods: Quantitative polymerase chain reaction was performed to determine the expression of FUT genes in synovial tissue from RA and osteoarthritis (OA) patients and in fluorescence‐activated cell–sorted cells from RA synovial fluid. The in vivo inhibitory effect of 2‐d‐gal was evaluated in a murine collagen‐induced arthritis (CIA) model. The in vitro effects of 2‐d‐gal on differentiation of inflammatory macrophages, production of cytokines, and antigen uptake, processing, and presentation functions were analyzed.Results: FUTs that are involved in terminal or subterminal fucosylation, but not those involved in core fucosylation or O‐fucosylation, were up‐regulated in RA compared to OA synovial tissue. The expression of terminal FUTs was highly positively correlated with the expression of TNF (encoding for tumor necrosis factor α). Terminal FUTs were predominantly expressed in M1 macrophages. In vivo, 2‐d‐gal treatment of mice precluded the development of CIA by reducing inflammatory macrophages and Th17 cells in the draining lymph nodes and decreasing the levels of TNFα, interleukin‐6 (IL‐6), and antibodies to type II collagen in the serum. In vitro, treatment with 2‐d‐gal skewed the differentiation of M1 macrophages to IL‐10–producing M2 macrophages. Furthermore, 2‐d‐gal significantly inhibited the antigen‐presenting function of M1 macrophages.Conclusion: Terminal fucosylation is a novel hallmark of inflammatory macrophages. Inhibition of terminal FUTs reshapes the differentiation and functions of M1 macrophages, leading to resolution of inflammation in arthritis.

22 October 2019 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
TKTakayuki Katsuyama
Takayuki Katsuyama
HLHao Li
Hao Li
Denis ComteDenis Comte
Denis Comte
GTGeorge Tsokos
George Tsokos
VMVaishali R. Moulton
Vaishali R. Moulton
Systemic lupus erythematosus (SLE) is a devastating autoimmune disease, in which hyperactive T cells play a critical role. Understanding molecular mechanisms underlying the T cell hyperactivity will lead to identification of specific therapeutic targets. Serine/arginine-rich splicing factor (SRSF)1 is an essential RNA-binding protein which controls posttranscriptional gene expression. We have demonstrated that SRSF1 levels are aberrantly decreased in T cells from SLE patients and correlate with severe disease, yet the role of SRSF1 in T cell physiology and autoimmune disease is largely unknown. Here we show that T cell-restricted Srsf1-deficient mice develop systemic autoimmunity and lupus-nephritis. Mice exhibit increased frequencies of activated/effector T cells producing proinflammatory cytokines, and an elevated T cell activation gene signature. Mechanistically, we noted increased activity of the mechanistic target of rapamycin (mTOR) pathway and reduced expression of its repressor PTEN. The mTOR complex (mTORC)1 inhibitor rapamycin suppressed proinflammatory cytokine production by T cells and alleviated autoimmunity in Srsf1-deficient mice. Of direct clinical relevance, PTEN levels correlated with SRSF1 in T cells from SLE patients, and SRSF1 overexpression rescued PTEN, suppressed mTORC1 activation and proinflammatory cytokine production. Our studies reveal the role of a previously unrecognized molecule SRSF1 in restraining T cell activation and averting the development of autoimmune disease and a potential therapeutic target for lupus.

17 June 2022 in Science Advances
Verified
Journal Article
Open access
PCPing-Min Chen
Ping-Min Chen
EKEri Katsuyama
Eri Katsuyama
ASAbhigyan Satyam
Abhigyan Satyam
HLHao Li
Hao Li
JRJose Rubio
Jose Rubio
GTGeorge Tsokos
George Tsokos
Infection is one of the major causes of mortality in patients with systemic lupus erythematosus (SLE). We previously found that CD38, an ectoenzyme that regulates the production of NAD + , is up-regulated in CD8 + T cells of SLE patients and correlates with the risk of infection. Here, we report that CD38 reduces CD8 + T cell function by negatively affecting mitochondrial fitness through the inhibition of multiple steps of mitophagy, a process that is critical for mitochondria quality control. Using a murine lupus model, we found that administration of a CD38 inhibitor in a CD8 + T cell–targeted manner reinvigorated their effector function, reversed the defects in autophagy and mitochondria, and improved viral clearance. We conclude that CD38 represents a target to mitigate infection rates in people with SLE.